Award Highlights the Promise of the Company’s New Class of Diagnostics
BOSTON – September 30, 2021 – Day Zero Diagnostics, Inc., an infectious disease diagnostics company harnessing the power of whole-genome sequencing and machine learning to combat the rise of antibiotic-resistant infections, has won the 2021 Disruptive Technology Award from The American Association for Clinical Chemistry (AACC) and the Audience Choice Award.
AACC is a global scientific and medical professional organization dedicated to clinical laboratory science and its application to healthcare. The Disruptive Technology Award recognizes innovative testing and disruptive technology solutions that improve patient care through diagnostic performance or access to high-quality testing. This year, the award was focused on artificial intelligence and machine learning technologies that are advancing medicine and pathology.
Jong Lee, President and CEO, presented the Day Zero technology, along with fellow finalists Mammoth Biosciences and MeMed, to a panel of expert judges at the 2021 AACC Annual Scientific Meeting which took place in Atlanta, GA. All presented testing solutions were judged on feasibility, data support, performance differentiation, and disruptive potential. In addition, Day Zero also won the Audience Choice award based on audience votes during the finalist competition.